CustomCustomCustomCustomCustomCustom
27 08, 2026

TAmiRNA at the 5th MC/WG Meeting of COST Action AtheroNET in Prague

2026-08-27T09:15:39+02:00August 27th, 2026|biomarker, Conference, RNA, small RNA-sequencing, smallRNA|0 Comments

From September 2–4, 2026, the COST Action AtheroNET (CA21153) network will gather for its 5th Management Committee and Working Group meeting at the University of Chemical Technology in Prague. AtheroNET is supported by COST (European Cooperation in Science and Technology) and connects European research groups working on new approaches to understanding and diagnosing atherosclerosis. The three-day programme promises intensive scientific exchange: from a keynote lecture on B cells and humoral immunity as modulators of residual cardiovascular risk, through sessions from all four Working Groups (cardioprotection and immune mechanisms, omics-based risk stratification, standardisation and ring trials, and AI/multi-omics methods), to two Young Researchers & Innovators sessions and a poster session. We are especially pleased that Dr. Matthias Hackl, [...]

Read More
31 07, 2026

TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026

2026-08-27T09:09:04+02:00July 31st, 2026|biomarker, circulating miRNAs, Conference, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, RNA, small RNA-sequencing, smallRNA|Comments Off on TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026

Our CEO Dr. Matthias Hackl, a leading expert in microRNA biomarker discovery, small RNA sequencing, and IVD development, has been invited as a lecturer at this year's Jyväskylä Summer School at the University of Jyväskylä, Finland. As part of the course BIO1: MicroRNA Biology and Function (4–6 August 2026), he will join an international team of experts from Helsinki, Kuopio, and Jyväskylä to deliver a lecture on microRNA biomarker discovery, validation, and clinical application, titled: "microRNAs as Biomarkers: Discovery, Validation, and the Path to Clinical Application" Participants will: Understand what constitutes a clinically useful biomarker and how signal-to-noise ratio and pre-analytical, analytical, and biological variability impact biomarker study design Learn how small RNA sequencing (next-generation sequencing, NGS) [...]

Read More
20 07, 2026

Circulating microRNAs Reveal Molecular Effect of Zoledronic Acid on Tendon-to-Bone Healing

2026-07-20T09:10:58+02:00July 20th, 2026|Biomarker Discovery, biomarkers, microRNA, microRNA services, microRNAs|Comments Off on Circulating microRNAs Reveal Molecular Effect of Zoledronic Acid on Tendon-to-Bone Healing

New publication in the American Journal of Sports Medicine, co-authored by TAmiRNA Retears remain a common complication after arthroscopic rotator cuff repair. A recent study by researchers from the AUVA Trauma Center Vienna-Meidling, the Ludwig Boltzmann Institute for Traumatology, the Austrian Cluster for Tissue Regeneration, and TAmiRNA now sheds light on the molecular mechanism behind a promising augmentation strategy: a single intraoperative dose of zoledronic acid. Background: A prior trial showed that a single systemic dose of zoledronic acid reduces retear rates in non-osteoporotic patients after rotator cuff repair. This follow-up study investigated the underlying biology by profiling circulating miRNAs linked to inflammation, fibrosis, and tendon-to-bone healing. Design: In a single-center, randomized, placebo-controlled, triple-blinded phase II trial, [...]

Read More
11 03, 2026

TAmiRNA @ RNA Leaders Europe Conference

2026-03-11T10:10:00+01:00March 11th, 2026|biomarker, circulating miRNAs, Conference, microRNA, microRNA services, NGS, RNA|Comments Off on TAmiRNA @ RNA Leaders Europe Conference

Vienna, Austria – 17.-19. March 2026 TAmiRNA is pleased to announce that CEO/CSO Matthias Hackl and Head of R&D Teresa Krammer will attend the upcoming RNA Leaders Europe Conference, one of the leading industry events dedicated to RNA therapeutics, innovation, and translational research. RNA Leaders Europe brings together key stakeholders from academia, biotech, pharma, and technology providers to discuss the latest scientific advances, regulatory developments, and commercialization strategies in the rapidly evolving RNA field. As a specialized provider of RNA-focused services, TAmiRNA supports partners worldwide with comprehensive solutions ranging from RNA profiling and biomarker discovery to advanced bioinformatics and customized data analysis. The conference offers an excellent platform to exchange insights, explore collaborations, and discuss how cutting-edge [...]

Read More
2 03, 2026

Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

2026-03-02T10:12:31+01:00March 2nd, 2026|biomarker, circulating miRNAs, Illumina NewSeq2000, microRNA, microRNA services, NGS, T1D, Type 1 Diabetes|Comments Off on Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

TAmiRNA is proud to contribute to a newly published peer-reviewed study demonstrating the independent validation of circulating microRNAs (miRNAs) as biomarkers in adolescents with long-standing type 1 diabetes (T1D). The study, published in PLOS ONE (2026), strengthens growing evidence that circulating microRNAs serve as minimally invasive biomarkers with potential applications in disease monitoring and precision medicine. Study Overview: microRNA Biomarkers in Adolescent Type 1 Diabetes Reliable biomarkers are essential for improving disease monitoring and long-term management of type 1 diabetes. MicroRNAs — small, non-coding RNA molecules regulating gene expression — are detectable in blood and have emerged as promising non-invasive diagnostic and prognostic tools. This case-control study investigated previously reported circulating miRNAs in: 24 adolescents with type [...]

Read More
21 10, 2025

TAmiRNA @ Precision Medicine EV Forum

2025-10-21T11:40:23+02:00October 21st, 2025|biomarker, Biomarker Discovery, biomarkers, congress, exosomes, extracellular vesicle, isomiR, microRNA, microRNAs, small RNA-sequencing|Comments Off on TAmiRNA @ Precision Medicine EV Forum

TAmiRNA to Exhibit at the Precision Medicine EV Forum 2025 in Cambridge Vienna, October 2025 – TAmiRNA GmbH, a leading provider of extracellular vesicle (EV) transcriptomic services, is pleased to announce its participation as an exhibitor at the Precision Medicine EV Forum 2025, taking place in Cambridge, UK, from October 27th to 28th. The forum, a key event focused on the translational aspects of EV research, provides a platform for TAmiRNA to showcase its cutting-edge solutions for biomarker discovery and therapeutic development. Meet Our Experts Our CEO/CSO, Matthias Hackl, PhD, and Scientific Consultant, Magdalena Mecking, MSc, will be on-site to meet with researchers and industry leaders. They will be available to discuss how TAmiRNA’s proprietary workflows and [...]

Read More
14 10, 2025

hepatoMX Project Kickoff: TAmiRNA and You2Yourself Join Forces to Develop a Groundbreaking Urinary microRNA Diagnostic for Liver Disease

2025-10-14T08:25:31+02:00October 14th, 2025|biomarker, Biomarker Discovery, biomarkers, hepatoMX, Illumina NewSeq2000, microRNA services, microRNAs, miND, miND spike ins, NGS, sequencing, small RNA-sequencing, smallRNA|Comments Off on hepatoMX Project Kickoff: TAmiRNA and You2Yourself Join Forces to Develop a Groundbreaking Urinary microRNA Diagnostic for Liver Disease

We are excited to announce the official start of the EUREKA Eurostars project hepatoMX — a three-year collaboration between You2Yourself (Y2Y), a Dutch company specializing in small RNA-based early disease detection, and TAmiRNA GmbH, an Austrian SME with expertise in microRNA biomarker discovery and diagnostic test development (hepatomiR®). The project officially started on April 1, 2025, and aims to revolutionize the early detection of metabolic liver disease. The hepatoMX project will leverage TAmiRNA’s clinical expertise in liver diagnostics and Y2Y’s unique Urimon cohort that captures the dynamics of disease development to deliver a validated diagnostic test utilizing a proprietary urinary microRNA biomarker panel to identify early-stage liver disease in a simple and non-invasive manner. This innovative approach [...]

Read More
9 10, 2025

Microvascular microRNA Signatures in Sepsis: A High-Resolution View

2025-10-09T10:29:18+02:00October 9th, 2025|biomarker, Biomarker Discovery, biomarkers, Illumina NewSeq2000, laser microdissection (LMD), microRNA services, microRNAs, miND, miND spike ins, NGS, sequencing, small RNA-sequencing, smallRNA|Comments Off on Microvascular microRNA Signatures in Sepsis: A High-Resolution View

Sepsis drives profound microvascular injury, particularly in the kidney. But how do microRNAs (miRNAs) - the small regulators of gene expression - respond within distinct vascular compartments during this insult? A new study by Luxen et al.  published in Scientific Reports on October 2nd 2025 takes on this question using a clever methodological combination: laser microdissection (LMD) of microvascular subregions (arterioles, glomeruli, capillaries, postcapillary venules) followed by small RNA sequencing using TAmiRNA´s miND® workflow for highly sensitive and quantitative microRNA analysis. Why this approach matters Traditional microRNA profiling of whole tissues obscures spatial heterogeneity. With LMD, the authors could precisely isolate defined microvascular zones from kidney sections. Even with the tiny RNA yields from these isolated compartments, [...]

Read More
22 09, 2025

TAmiRNA @ GSEV 2025

2025-09-22T08:52:59+02:00September 22nd, 2025|biomarker, Biomarker Discovery, biomarkers, microRNAs, NGS, periprosthetic joint infections, small RNA-sequencing, Synovial fluid|Comments Off on TAmiRNA @ GSEV 2025

TAmiRNA Announces Gold Sponsorship of GSEV Autumn Meeting 2025 and Presentation by Matthias Hackl TAmiRNA, a pioneer in transcriptomics-based biomarker research, is proud to announce its participation as a Gold Sponsor at the GSEV Autumn Meeting 2025, hosted by the German Society for Extracellular Vesicles (GSEV). The annual conference will take place on September 25–26, 2025, at the Audimax of the University Hospital Essen. As part of the scientific program, Matthias Hackl (TAmiRNA) will deliver a presentation on Thursday, September 25, at 12:15 pm entitled: “Small RNA-sequencing (miND®) Enables Discovery of EV-specific MicroRNA Signatures to Support EV Therapeutics Development.” “Using miND®, we can robustly identify EV-specific microRNA signatures – a critical step toward enabling data-driven research and [...]

Read More
8 09, 2025

TAmiRNA @ EBJIS 2025

2025-09-17T11:35:44+02:00September 8th, 2025|biomarker, Biomarker Discovery, biomarkers, microRNAs, NGS, periprosthetic joint infections, small RNA-sequencing, Synovial fluid|Comments Off on TAmiRNA @ EBJIS 2025

TAmiRNA is proud to announce its participation at the upcoming European Bone and Joint Infection Society (EBJIS) Meeting 2025 in Ferrara, Italy. On Thursday, September 11, 2025 at 11:00 (Sala Emilia), Dr. Bernhard JH Frank will present groundbreaking new results from a collaborative study conducted with the Orthopaedic Hospital Speising and Dr. Jochen G. Hofstätter. The presentation is entitled: “Synovial fluid microRNA biomarkers enable accurate diagnosis of hip and knee periprosthetic joint infections.” Synovial fluid microRNA biomarkers for accurate PJI diagnosis Periprosthetic joint infection (PJI) is one of the most severe complications after hip and knee replacement surgery. Accurate and timely diagnosis remains a clinical challenge due to limited sensitivity and specificity of current diagnostic methods. In [...]

Read More
© Copyright TAmiRNA 2019 - 
Go to Top